USFDA clears Indoco’s Goa Plant II and III
The inspection was held from 27th May, 2019 to 4th June, 2019, where the company had received four observations (483s)
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Indoco Remedies
Indoco’s Goa Plant I receives Warning Letter from US FDA
The facility had received six observations in Form 483s and was classified as ‘OAI’ (Official Action Indicated’) in March 2019
Indoco Remedies gets warning letter from USFDA for oral dosages plant in Goa
The company has received a warning letter from the United States Food and Drug Administration (USFDA) as a result of the…
Panel discussion: Bridging the gap between exhibit batches and day-to-day manufacturing
FDD Conclave 2019 focussed on the theme, 'Preparing for the next frontiers in FDD'. And, a great deal of being future-ready…
FEEDBACK TO FDD Conclave 2019
FDD Conclave 2019, Dr Ramesh Jhawar, Ajanta Pharma , Sapna Ramesh, Indoco Remedies,
ravikumar n, MSN Labortories, ulhas Dhuppad,…
Trial by fire
Born just a week after India gained independence, Indoco Remedies has witnessed and been a part of the trials and triumphs of the…
Indoco Remedies Q4 net profit rises 6.7 per cent to Rs 20 crores aided by exports
Recommends 10 per cent final dividend in addition to 70 per cent interim dividend announced earlier
Indoco Remedies receives US FDA nod for Goa manufacturing facility
The approval confirms the closure of inspection conducted in July 2015
Maharashtra, the pharma capital
Suresh G Kare, Chairman, Indoco Remedies, elaborates why Maharashtra has been a preferred destination for the pharma sector
Indoco Remedies receives USFDA nod for solid dosages plant I in Goa
The plant has a capacity to manufacture 2.2 billion tablets, 32 million bottles of liquid orals, 16 million tubes of creams and…